|
|
Volumn 22, Issue 4, 2003, Pages 119-127
|
|
Good science and the marketplace for drugs: a conversation with Jean-Pierre Garnier. Interview by John K. Iglehart.
a
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
GENERIC DRUG;
VACCINE;
AGED;
ARTICLE;
COST BENEFIT ANALYSIS;
DEVELOPING COUNTRY;
DRUG COST;
DRUG INDUSTRY;
ECONOMICS;
HEALTH CARE COST;
HEALTH INSURANCE;
HUMAN;
INTERVIEW;
MEDICARE;
ORGANIZATION AND MANAGEMENT;
RESEARCH;
UNITED STATES;
AGED;
COST-BENEFIT ANALYSIS;
DEVELOPING COUNTRIES;
DRUG COSTS;
DRUG INDUSTRY;
DRUGS, GENERIC;
HEALTH CARE SECTOR;
HUMANS;
INSURANCE, PHARMACEUTICAL SERVICES;
MEDICARE;
RESEARCH;
UNITED STATES;
VACCINES;
MLCS;
MLOWN;
|
|
EID: 0042161749
PISSN: 02782715
EISSN: None
Source Type: Journal
DOI: 10.1377/hlthaff.22.4.119 Document Type: Article |
|
Times cited : (6)
|
|
References (0)
|
